Zhitong Finance App learned that in the context of biotech IPOs crushing the AI sector with an average return of 55% and becoming the biggest winner in US stocks in 2026, another clinical-stage biopharmaceutical company supported by top venture capital has joined the listing boom. Braveheart Bio Inc. (BRVE.US), supported by Andreessen Horowitz (a16z), announced on Wednesday the expansion of the IPO, issuing 21.25 million shares at a price of 18 US dollars per share, raising a total of 382.5 million US dollars — not only did the pricing break the previous upper limit of the 15 to 17 US dollar range, but the issuance scale was also significantly larger than the original plan of 18.75 million shares. The San Francisco-based cardiovascular disease drug developer has a market capitalization of approximately $1.27 billion at the IPO price.
Distribution Overview: From $318 Million to $382.5 Million “Oversubscribed”
Braveheart Bio secretly submitted an IPO application to NASDAQ in mid-July and officially announced the terms of sale on July 30. It plans to issue 18.75 million shares at a price of 15 to 17 US dollars each, with a target capital of about 318.8 million US dollars. However, strong demand from investors drove the company to significantly expand its offering before pricing — eventually issuing 21.25 million shares, priced at $18, and raising a total of $382.5 million. The underwriter was also granted a 30-day over-allotment right to purchase up to an additional 3.187,500 shares.
Goldman Sachs, Jefferies, TD Cowen, Stifel, and Cantor Fitzgerald acted as joint bookkeepers for this offering. The stock officially began trading on the NASDAQ Global Market on August 6. The code is “BRVE”, and delivery is expected to be completed on August 7.
Core pipeline: BHB-1893 targets the 10 billion hypertrophic cardiomyopathy market
Established in 2024, Braveheart Bio is a late-clinical biopharmaceutical company focused on developing innovative treatments for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.
The company's core drug candidate BHB-1893 (also known as HRS-1893) is an oral small-molecule cardiomyosin inhibitor that specifically inhibits myocardial myosin ATPase activity, normalizes myocardial contractile performance, reduces left ventricular hypertrophy, and improves diastolic compliance. The drug obtained an exclusive global license (excluding Greater China) from Jiangsu Hengrui Pharmaceutical in China in September 2025.
Clinical data highlights:
Obstructive hypertrophic cardiomyopathy (OHCM): A randomized, open-label phase II clinical trial involving 42 symptomatic OHCM patients showed that BHB-1893 can quickly and significantly reduce left ventricular outlet pressure difference (LVOT-G), improve patients' exercise tolerance and symptoms, and has minimal effect on left ventricular ejection fraction and is safe. The complete remission rate was as high as 86%.
Non-obstructive hypertrophic cardiomyopathy (NHCM): Another phase II study showed that BHB-1893 can rapidly and continuously reduce key cardiac biomarkers, improve cardiac diastolic function and cardiac structural indicators. Patients reported improvements in symptoms and exercise ability, and overall tolerability.
Based on these positive results, Hengrui Pharmaceutical has initiated phase III clinical trials in China in 2025, Braveheart Bio plans to independently launch the global OHCM phase III trial (LIONHEART-HCM) in the second half of 2026, and the NHCM phase III trial (NOBLEHEART-HCM) in the first half of 2027.
Investors' “all-star lineup”: a16z leads, Baijian CEO sits in
Braveheart Bio's shareholder lineup is extravagant. In November 2025, the company officially unveiled with $185 million Series A funding round. Investors include Andreessen Horowitz (a16z Bio + Health), Forbion (expected to drop to 22% after listing), OrbiMed (expected to hold 12%), Enavate Sciences (a platform owned by Patient Square Capital), and Frazier Life Sciences.
After the listing, a16z is expected to hold approximately 11% of the shares. What is more noteworthy is that Christopher Viehbacher, CEO of BIIB.US (BIIB.US), is the chairman of Braveheart.
The company's CEO Travis Murdoch, M.D., has more than 10 years of experience in life science investment and operation management. He founded Hi-Bio and led a $1.8 billion merger and acquisition deal with Baijian in 2024. Fidelity (Fidelity) also provided an important endorsement for this IPO with an anchor order of 75 million dollars, accounting for about a quarter of the mid-point price of the offering.
Market background: the “golden window” of biotech IPOs
Braveheart's successful listing was not an isolated event, but a microcosm of the full recovery of biotech IPOs in 2026. According to the data, the weighted average return on IPOs of US pharmaceutical companies since 2026 is as high as 64%, while the weighted average return on the overall IPO market after excluding financial instruments such as SPAC is only 1%. The biotech sector outperformed the market by more than 60 percentage points and became the biggest winner in the 2026 US IPO market.
Just this week, Attovia Therapeutics, another immunotherapy company supported by A16z, completed an IPO, and the pricing also fell to the upper end of the $15 to $17 range. The “golden window” for biotech IPOs continues to open.